Shuyuan Yao, Allogene Overland CEO
June 21, 2021 10:16 AM EDTUpdated 11:14 AM
People
China
Cell/Gene Tx

Al­lo­gene, Over­land woo an ex­pe­ri­enced hand from WuXi to steer their al­lo­gene­ic CAR-T JV

Amber Tong

Al­lo­gene Over­land Bio­pharm, the joint ven­ture David Chang and Ed Zhang set up to tur­bocharge the de­vel­op­ment of off-the-shelf CAR-T ther­a­pies in Chi­na, has locked …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times